RNS Out - looks promising24 Sep 2020 11:04
24/09/2020 10:00am
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
24 September 2020
Yourgene Health plc
("Yourgene" or the "Company")
DPD reimbursement in Germany
Manchester, UK - 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national reimbursement authority in Germany, has approved the reimbursement for testing of Dihydropyrimidine Dehydrogenase (DPD) deficiency in Germany, which opens up the clinical market in this region for the Company's first oncology genotyping product, the Elucigene DPYD Test. The preliminary reimbursement figure for DPD testing is set at 120 EUR for each patient test. The scheme commences on the 1 October 2020 and has not at this stage specified any commercial products or technologies.
Elucigene DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU is metabolized by the DPD enzyme which is encoded by the DPYD gene.
The Committee for Risk Assessment in the field of pharmacovigilance of the European Medicines Agency and the Federal Institute for Medicinal Products and Medical Devices have determined the benefits of the DPD test, highlighting patients with an absence or deficiency of the DPD enzyme to have an increased risk of severe or life threatening toxicity. The reimbursement will fall under the EBM scheme, which covers the largest number of patients (approx. 80% of the population).
Lyn Rees, CEO of Yourgene Health said: "We expect this reimbursement approval to help accelerate our growth in this key market, aided by having a direct sales presence, enabling us to capitalise on this opportunity."
Sign In
Follow the stocks
